{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-014909","form_type":"8-K","ticker":"GNPX","cik":"0001595248","company_name":"Genprex, Inc.","filed_at":"2025-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.940454+00:00","generated_at":"2026-05-22T08:09:55.992993+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Genprex enters new sponsored research agreement with University of Pittsburgh for GPX-002 diabetes gene therapy","bullets":["New SRA with Pitt for preclinical studies of GPX-002 in T1D and T2D animal models.","Preclinical T1D data showed statistically significant decreases in insulin requirements and increases in c-peptide levels.","GPX-002 uses adeno-associated virus vector with Pdx1 and MafA genes delivered via pancreatic duct.","In T1D, GPX-002 aims to transform alpha cells into functional beta-like cells to evade immune system.","In T2D, GPX-002 is believed to rejuvenate exhausted beta cells."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-014909","json":"https://secwatch.observer/filing/0001437749-25-014909.json","markdown":"https://secwatch.observer/filing/0001437749-25-014909.md","text":"https://secwatch.observer/filing/0001437749-25-014909.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1595248/000143774925014909/0001437749-25-014909-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1595248/000143774925014909/gnpx20250506_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-22T08:09:55.992993+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}